LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Home・Stock List・Vivani Medical

Vivani Medical

Open

1.46 3.55

Buy Sell

Overview

Share price change

24h

Current

Min

1.37

Max

1.53

Key metrics
By Trading Economics
Employees	37

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+230.58% upside

Dividends
By Dow Jones
Next Earnings	12 Nov 2025

Market Stats
By TradingEconomics
Market Cap	3.7M 68M
Previous open	-2.09
Previous close	1.46

Vivani Medical Chart

Past performance is not a reliable indicator of future results.

Related News

17 Sept 2025, 23:01 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 Sept 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 Sept 2025, 21:59 UTC

Earnings

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 Sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 Sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 Sept 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 Sept 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 Sept 2025, 21:00 UTC

Earnings

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 Sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 Sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 Sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 Sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 Sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 Sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 Sept 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 Sept 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 Sept 2025, 16:51 UTC

Earnings

Correct: Exor 1H Net Loss -EUR624M

17 Sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 Sept 2025, 16:25 UTC

Earnings

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 Sept 2025, 16:23 UTC

Earnings

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Comparison

Price change

Vivani Medical Forecast

Price Target

By TipRanks

230.58% upside

12 Months Forecast

Average 4 USD 230.58%

High 4 USD

Low 4 USD

Based on 2 Wall Street analysts offering 12 month price targets forVivani Medical - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Vivani Medical - Dist in the past 3 months.

Financials

About Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.